McKesson Corporation stock (US58155Q1031): institutional buying and insider filing in focus

McKesson Corporation shares traded around the mid-740 USD range on the NYSE on 06/01/2026 as fresh 13F disclosures showed new institutional positions while a recent Form 144 highlighted planned insider share sales, keeping ownership trends in the United States center stage.

McKesson Corporation shares changed hands around the mid-740 USD level on the New York Stock Exchange on 06/01/2026, with Google Finance data showing an opening price of USD 741.47 for NYSE:MCK that day, underscoring the company’s role as a large-cap healthcare distributor in the United States equity market.Google Finance as of 06/01/2026

The latest institutional ownership updates reported in the United States included a 13F disclosure that MUFG Securities EMEA plc held approximately USD 4.15 million in McKesson shares as referenced on 06/01/2026, while a separate filing showed that Ellevest Inc. initiated a new position in the stock, highlighting continued interest from professional investors in the US healthcare supply chain.MarketBeat as of 06/01/2026 According to a recent SEC Form 144 notice filed by an affiliate of McKesson in late May 2026, the company reported restricted stock vesting between 05/19/2026 and 05/23/2026 with an intention to sell common stock through Fidelity Brokerage Services, signaling potential insider share sales but without confirming execution details.SEC/Form 144 summary as of 05/23/2026

The stock traded at 742.44 USD on a recent close on the NYSE, according to MarketScreener data citing the last close price for McKesson, illustrating that the current quotation remains in a tight band around that reference level.MarketScreener as of 05/31/2026 In Germany, McKesson can also be accessed via trading venues such as Tradegate under its ISIN US58155Q1031, giving European investors an additional route to gain exposure to the US-listed healthcare distributor in euro terms.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: McKesson
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Irving, United States
• Core markets: United States and selected international markets
• Key revenue drivers: Pharmaceutical distribution, medical-surgical supplies, and technology-enabled healthcare solutions
• Home exchange/listing venue: New York Stock Exchange (MCK)
• Trading currency: USD

McKesson Corporation: core business model

McKesson operates as a large-scale healthcare intermediary that moves pharmaceuticals and medical products through its US and international networks while also providing technology and services that help providers and payers manage clinical and supply-chain workflows.MarketScreener company profile as of 05/31/2026

Recent corporate actions

The Form 144 filing submitted in late May 2026 indicated that an affiliate of McKesson planned to sell shares that had vested as restricted stock on several dates between 05/19/2026 and 05/23/2026, with Fidelity Brokerage Services named as broker, which is a standard regulatory step for selling control or restricted securities in the United States.SEC/Form 144 summary as of 05/23/2026 Around the same broader period, media reports and database entries also highlighted Norges Bank emerging as a notable shareholder, adding to signals that the company’s share register is seeing both institutional inflows and planned insider-related sales in 2026.Google Finance news overview as of 05/2026

What banks and research houses say about McKesson Corporation

According to MarketBeat data cited on 06/01/2026, McKesson carries a consensus rating of "Moderate Buy" across the analyst community, with an average price target of about USD 968.87, and the same source notes that sell-side analysts expect the company to generate earnings per share of roughly 44.29 for its current fiscal year.MarketBeat as of 06/01/2026 Management has outlined guidance for FY 2027 in a range of USD 43.80 to USD 44.60 in adjusted earnings per share, again referenced by MarketBeat on 06/01/2026, providing a numerical anchor for how research houses are calibrating their models for the US-listed group over the coming fiscal period.MarketBeat guidance excerpt as of 06/01/2026

While individual price targets and ratings differ by institution, the combination of a consensus positive stance and detailed earnings expectations illustrates that McKesson remains firmly on the radar of US and international research desks that specialize in healthcare and distribution stocks, especially as the company executes on its long-term strategy in pharmaceutical and medical-surgical supply chains.

Conclusion

The latest trading data on the NYSE, combined with fresh 13F disclosures from MUFG Securities EMEA plc and Ellevest Inc., underscore that McKesson Corporation remains an actively followed United States healthcare stock with ongoing institutional interest and visible insider-related filing activity. The Form 144 notice filed in late May 2026 points to potential share sales from vested restricted stock, adding another element to the evolving ownership picture alongside large investors such as Norges Bank. Against this backdrop, the current analyst consensus of "Moderate Buy" with an average price target around the high-900 USD area and detailed EPS expectations into FY 2027 provides additional reference points for how the market is framing McKesson’s earnings profile and risk-reward characteristics without implying any specific investment view.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.